CLSI and EUCAST 2014 Breakpoints for MIC testing
First Comprehensive Evaluation of the M I C Evaluator Device Compared to Etest and CLSI Broth Microdilution for MIC Testing of Aerobic Gram Positive and Gram Negative Bacterial Species
6
Evaluation of Oxacillin and Cefoxitin Disk Diffusion and MIC Breakpoints Established by the Clinical and Laboratory Standards Institute for Detection of mecA Mediated Oxacillin Resistance in Staphylococcus schleiferi
10
Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
5
Antimicrobial susceptibility of strains of Enterobacteriaceae isolated from bloodstream infections using current CLSI and EUCAST breakpoints
5
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI Breakpoints
8
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species
8
Development of Doxycycline MIC and Disk Diffusion Interpretive Breakpoints and Revision of Tetracycline Breakpoints for Streptococcus pneumoniae
5
International and Multicenter Comparison of EUCAST and CLSI M27 A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp to Fluconazole, Itraconazole, Posaconazole, and Voriconazole
6
Normalized Resistance Interpretation as a Tool for Establishing Epidemiological MIC Susceptibility Breakpoints
8
Susceptibility of Extended Spectrum β Lactamase Producing Enterobacteriaceae According to the New CLSI Breakpoints
5
Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI Breakpoints
7
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
10
Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community acquired respiratory tract infections?
9
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
8
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
8
Multicenter Evaluation of the New Vitek 2 Yeast Susceptibility Test Using New CLSI Clinical Breakpoints for Fluconazole
5
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints
7
Comparative Evaluation of a New Commercial Colorimetric Microdilution Assay (SensiQuattro Candida EU) with MIC Test Strip and EUCAST Broth Microdilution Methods for Susceptibility Testing of Invasive Candida Isolates
7
Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology
5
Comparative Antimicrobial Susceptibility Profiles of Uropathogenic Extended-Spectrum ß-Lactamase Producing Strains of Klebsiella pneumonia and Escherichia coli by the CLSI and EUCAST Methodologies
13